Last reviewed · How we verify
Dichystrolum (DIHYDROTACHYSTEROL)
Dichystrolum (generic name: DIHYDROTACHYSTEROL) is a dihydrotachysterol drug. It is currently in Phase 2 development for Hypocalcemia, Hypoparathyroidism, Hypophosphatemia.
Dichystrolum works by activating the Vitamin D3 receptor to increase calcium levels in the body.
Dichystrolum is a small molecule that acts as a vitamin D3 receptor agonist. It belongs to the drug class of agonists and is known by various synonyms, including A.T. 10, DIHIDROTAQUISTEROL, and DIHYDROTACHYSTEROL.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | DIHYDROTACHYSTEROL |
|---|---|
| Drug class | dihydrotachysterol |
| Target | Vitamin D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 2 |
Mechanism of action
Think of Vitamin D3 like a key that unlocks a door to allow calcium to enter your cells. When Dichystrolum binds to the Vitamin D3 receptor, it's like giving the key to the door, allowing calcium to flow in and helping to regulate your body's calcium levels.
Approved indications
- Hypocalcemia
- Hypoparathyroidism
- Hypophosphatemia
- Rickets
- Tetany
Common side effects
Key clinical trials
- Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart Devices
- Digital Health Intervention for Children With ADHD (NA)
- Exercise and Movement to Enhance Resiliency in Cancer Patients (NA)
- Hypertension Chronobiome
- AI-Driven MRF Type 2 Diabetes Integrating DHT IF and Resistance Training to OM and Functional Outcomes (NA)
- Dual-target, High-dose TMS for PD Patients With FOG (NA)
- Testing the Epley Maneuver for Treating Dizziness in the Emergency Department: A Randomized Study (NA)
- Assessment of Usability and Preliminary Effectiveness of a Digital Sleep Aid in an Italian Sample (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dichystrolum CI brief — competitive landscape report
- Dichystrolum updates RSS · CI watch RSS
Frequently asked questions about Dichystrolum
What is Dichystrolum?
How does Dichystrolum work?
What is Dichystrolum used for?
What is the generic name of Dichystrolum?
What drug class is Dichystrolum in?
What development phase is Dichystrolum in?
What does Dichystrolum target?
Related
- Drug class: All dihydrotachysterol drugs
- Target: All drugs targeting Vitamin D3 receptor
- Therapeutic area: All drugs in Nephrology
- Indication: Drugs for Hypocalcemia
- Indication: Drugs for Hypoparathyroidism
- Indication: Drugs for Hypophosphatemia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing